Mainz Biomed said on Friday that it has initiated a clinical study to evaluate the integration of mRNA biomarkers into its ColoAlert colorectal cancer test.
ColoAlert is a CE-marked PCR-based test designed to detect tumor DNA in stool samples. In January, Mainz acquired an exclusive option to license a collection of mRNAs from the Universite de Sherbrooke that have shown potential as biomarkers of curable precancerous colonic polyps and treatable early-stage colorectal cancer.